Skip to main content

Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ: AGIO · IEX Real-Time Price · USD
46.66 -0.08 (-0.17%)
Sep 23, 2021 11:41 AM EDT - Market open
Market Cap2.76B
Revenue (ttm)78.75M
Net Income (ttm)1.59B
Shares Out69.94M
EPS (ttm)23.67
PE Ratio1.97
Forward PE2.47
Dividendn/a
Ex-Dividend Daten/a
Volume65,711
Open46.98
Previous Close46.74
Day's Range46.34 - 47.44
52-Week Range32.47 - 62.16
Beta1.57
AnalystsBuy
Price Target62.43 (+33.8%)
Est. Earnings DateNov 4, 2021

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which...

IndustryBiotechnology
IPO DateJul 24, 2013
CEOJacqualyn Fouse
Employees562
Stock ExchangeNASDAQ
Ticker SymbolAGIO
Full Company Profile

Financial Performance

In 2020, AGIO's revenue was $203.20 million, an increase of 72.33% compared to the previous year's $117.91 million. Losses were -$327.37 million, -20.44% less than in 2019.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 62.43, which is an increase of 33.80% from the latest price.

Price Target
$62.43
(33.80% upside)
Analyst Consensus: Buy

News

Agios To Present at September Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...

3 weeks ago - GlobeNewsWire

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

4 weeks ago - InvestorPlace

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

1 month ago - Zacks Investment Research

Agios' Rare Anemia Drug Application Under FDA Priority Review

The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agency's ...

1 month ago - Benzinga

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with...

-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --

1 month ago - GlobeNewsWire

Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

1 month ago - Zacks Investment Research

Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades

With the trading day nearly halfway over, the broad markets were pulling back into the weekend.

1 month ago - 24/7 Wall Street

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Agios Reports Business Highlights and Second Quarter 2021 Financial Results

– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU –

1 month ago - GlobeNewsWire

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that t...

2 months ago - GlobeNewsWire

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

2 months ago - Zacks Investment Research

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults ...

CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...

2 months ago - GlobeNewsWire

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

3 months ago - Zacks Investment Research

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...

3 months ago - GlobeNewsWire

Agios Pharma Files US Application For Mitapivat In PK Deficiency

Agios Pharmaceuticals Inc (NASDAQ: AGIO) has submitted an FDA marketing application seeking approval for mitapivat to treat adults with pyruvate kinase (PK) deficiency. The company says, if approved, mi...

3 months ago - Benzinga

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...

3 months ago - GlobeNewsWire

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at ...

– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 –

3 months ago - GlobeNewsWire

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Defici...

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 –

3 months ago - GlobeNewsWire

American Airlines, Biogen, Dow and More Thursday Afternoon Analyst Calls

With the trading day about halfway over, the markets were moving higher, after being stuck in the doldrums for the first half of the week.

3 months ago - 24/7 Wall Street

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral...

– Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET –

4 months ago - GlobeNewsWire

Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

4 months ago - Zacks Investment Research

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Agios Reports Business Highlights and First Quarter 2021 Financial Results

– Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress –

4 months ago - GlobeNewsWire

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research